Spyre Therapeutics, Inc.

SYRESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1636282

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$886.0K	$2.3M	$18.7M	$0.00	$0.00
Research and Development Expense	—	—	—	$59.6M	$64.6M
Operating Expenses	$243.2M	$87.1M	$84.4M	$81.5M	$80.3M
Operating Income (Loss)	-$242.3M	-$84.8M	-$65.6M	-$81.5M	-$80.3M
Nonoperating Income (Expense)	-$96.5M	$830.0K	-$11.0K	$588.0K	$2.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$338.8M	-$84.0M	-$65.7M	-$80.9M	-$78.3M
Income Tax Expense (Benefit)	-$26.0K	-$136.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$608.5M	$341.9M	$71.1M	$109.9M	$161.6M
Assets, Current	$608.5M	$341.5M	$62.3M	$98.9M	$149.8M
Cash and Cash Equivalents, at Carrying Value	$188.9M	$34.9M	$34.9M	$15.1M	$90.1M
Liabilities	$90.7M	$73.3M	$20.8M	$26.0M	$21.8M
Liabilities, Current	$54.1M	$32.0M	$14.7M	$20.1M	$16.4M
Accounts Payable, Current	—	—	—	$3.3M	$2.3M
Stockholders' Equity Attributable to Parent	$50.3M	$83.9M	$139.8M	$60.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$99.9M	-$80.1M	-$53.7M	-$75.8M	-$65.7M
Net Cash Provided by (Used in) Investing Activities	-$108.4M	$57.0M	-$22.6M	-$7.6M	-$1.7M
Net Cash Provided by (Used in) Financing Activities	$361.1M	$42.7M	$1.4M	$154.5M	$65.7M
Payments to Acquire Property, Plant, and Equipment	—	$38.0K	$573.0K	$4.3M	$1.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)